Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Which Lipids Should Be Analyzed for Diagnostic Workup and Follow-up of Patients with Hyperlipidemias?

Research output: Contribution to journalReviewpeer-review

  1. Symptoms Preceding Sports-Related Sudden Cardiac Death in Persons Aged 1-49 Years

    Research output: Contribution to journalReviewpeer-review

  2. Diagnosis and Management of Lymphatic Disorders in Congenital Heart Disease

    Research output: Contribution to journalReviewpeer-review

  3. Diabetes and the Risk of Sudden Cardiac Death

    Research output: Contribution to journalReviewpeer-review

  1. Impact of high glucose levels and glucose lowering on risk of ischaemic stroke: a Mendelian randomisation study and meta-analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Elevated apolipoprotein A1 and HDL cholesterol associated with age-related macular degeneration: 2 population cohorts

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Common variants in Alzheimer's disease and risk stratification by polygenic risk scores

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Plasma concentrations of magnesium and risk of dementia: a general population study of 102 648 individuals

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

PURPOSE OF REVIEW: To summarize and discuss the clinical use of lipid and apolipoprotein tests in the settings of diagnosis and therapeutic follow-up of hyperlipidemia.

RECENT FINDINGS: The joint consensus panel of the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) recently produced recommendations on the measurement of atherogenic lipoproteins, taking into account the strengths and weaknesses of analytical and clinical performances of the tests. Total cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, and calculated non-HDL cholesterol (= LDL + remnant cholesterol) constitute the primary lipid panel for hyperlipidemia diagnosis and cardiovascular risk estimation. LDL cholesterol is the primary target of lipid-lowering therapies. Non-HDL cholesterol or apolipoprotein B should be used as secondary therapeutic target in patients with mild-to-moderate hypertriglyceridemia, 2-10 mmol/l (175-880 mg/dl). Lipoprotein (a) is included in LDL cholesterol and should be measured at least once in all patients at cardiovascular risk, including to explain poor response to statin treatment.

Original languageEnglish
JournalCurrent Cardiology Reports
Volume20
Issue number10
Pages (from-to)88
ISSN1534-3170
DOIs
Publication statusPublished - 17 Aug 2018

ID: 56621711